Tae-Gwon Oh

Title: Tae-Gwon Oh: Innovator in Adenoviral Vector Technology.

Introduction

Tae-Gwon Oh is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of adenoviral vectors. His innovative work has the potential to impact vaccine delivery systems and cancer therapies.

Latest Patents

Tae-Gwon Oh holds 1 patent for his invention titled "Adenoviral vector not including replication competent adenovirus, and use thereof." This patent describes a novel adenoviral vector that does not include a replication-competent adenovirus. The recombinant E1/E3/E4-deleted adenoviral vector features an antigenic protein and an E4orf6 gene inserted in an E1 gene-deleted region. This invention demonstrates adenovirus productivity, antigen expression, neutralizing antibody production, and T cell induction abilities comparable to control groups. It is designed to serve as an effective carrier for various vaccines, including those for diseases and anti-cancer applications.

Career Highlights

Tae-Gwon Oh is associated with Cellid Co., Ltd., where he continues to advance his research and development efforts. His work is characterized by a commitment to innovation and excellence in the biotechnology sector.

Collaborations

Tae-Gwon Oh collaborates with notable colleagues, including Chang-Yuil Kang and Bongju Park. Their combined expertise enhances the research and development initiatives at Cellid Co., Ltd.

Conclusion

Tae-Gwon Oh's contributions to adenoviral vector technology exemplify the intersection of innovation and biotechnology. His work holds promise for improving vaccine delivery and cancer treatment strategies.